These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 29608685)

  • 41. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
    Hidalgo-Tenorio C; Pasquau J; Vinuesa D; Ferra S; Terrón A; SanJoaquín I; Payeras A; Martínez OJ; López-Ruz MÁ; Omar M; de la Torre-Lima J; López-Lirola A; Palomares J; Blanco JR; Montero M; García-Vallecillos C
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
    Walmsley S; Baumgarten A; Berenguer J; Felizarta F; Florence E; Khuong-Josses MA; Kilby JM; Lutz T; Podzamczer D; Portilla J; Roth N; Wong D; Granier C; Wynne B; Pappa K
    J Acquir Immune Defic Syndr; 2015 Dec; 70(5):515-9. PubMed ID: 26262777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
    Briand C; Dollfus C; Faye A; Kantor E; Avettand-Fenoel V; Caseris M; Descamps D; Schneider V; Tabone MD; Vaudre G; Veber F; Blanche S; Frange P
    J Antimicrob Chemother; 2017 Mar; 72(3):837-843. PubMed ID: 27999017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.
    Rokx C; Schurink CA; Boucher CA; Rijnders BJ
    J Antimicrob Chemother; 2016 Jun; 71(6):1632-6. PubMed ID: 26888910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
    Katlama C; Soulié C; Caby F; Denis A; Blanc C; Schneider L; Valantin MA; Tubiana R; Kirstetter M; Valdenassi E; Nguyen T; Peytavin G; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2016 Sep; 71(9):2646-50. PubMed ID: 27287235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
    Revollo B; Viñuela L; de la Mora L; García F; Noguera-Julián M; Parera M; Paredes R; Llibre JM
    J Antimicrob Chemother; 2022 May; 77(6):1738-1740. PubMed ID: 35274144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M; Parks DC; Ferrante S; Punekar Y
    AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
    Oldenbuettel C; Wolf E; Ritter A; Noe S; Heldwein S; Pascucci R; Wiese C; Von Krosigk A; Jaegel-Guedes E; Jaeger H; Balogh A; Koegl C; Spinner CD
    Antivir Ther; 2017; 22(2):169-172. PubMed ID: 27588613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
    Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B
    J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
    Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;
    J Antimicrob Chemother; 2017 Apr; 72(4):1163-1171. PubMed ID: 28093483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
    Fida M; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2019 May; 55(5):297-304. PubMed ID: 31131840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
    Charpentier C; Montes B; Perrier M; Meftah N; Reynes J
    J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.